Cargando…

Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan

BACKGROUND: Fabry disease is a rare X-linked lysosomal storage disorder. It is associated with physical distress and social challenges that may affect adults differently compared to pediatric patients. However, there is no disease-specific quality of life (QOL) scale that can provide a detailed asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Koto, Yuta, Yamashita, Wakana, Lee, Yoko, Hadano, Nozomi, Kokubu, Chikara, Sakai, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672224/
https://www.ncbi.nlm.nih.gov/pubmed/36394676
http://dx.doi.org/10.1186/s41687-022-00525-z
_version_ 1784832699092959232
author Koto, Yuta
Yamashita, Wakana
Lee, Yoko
Hadano, Nozomi
Kokubu, Chikara
Sakai, Norio
author_facet Koto, Yuta
Yamashita, Wakana
Lee, Yoko
Hadano, Nozomi
Kokubu, Chikara
Sakai, Norio
author_sort Koto, Yuta
collection PubMed
description BACKGROUND: Fabry disease is a rare X-linked lysosomal storage disorder. It is associated with physical distress and social challenges that may affect adults differently compared to pediatric patients. However, there is no disease-specific quality of life (QOL) scale that can provide a detailed assessment of QOL for adults with Fabry disease. Therefore, we aimed to determine the factor structure and assess the validity of a scale that was created to assess the QOL of adult patients with Fabry disease. This study was conducted in two phases. First, scale feasibility was confirmed through a questionnaire survey of nine patients. Second, a cross-sectional questionnaire survey of patients (aged ≥ 18 years) diagnosed with Fabry disease was conducted. Item development and refinement were conducted based on guidelines for scale development. Exploratory factor analysis was used to clarify the factor structure and confirm internal consistency. As a measure of QOL, construct validity was of the scale was verified based on its correlations with the Short Form-8 (SF-8) scale. RESULTS: The newly created Adult Fabry Disease QOL (AFQOL) scale comprises 39 items that cover five factors: “neuropathic pain and abdominal symptoms,” “impact on work and school,” “relationship challenges,” “ophthalmologic and otolaryngologic symptoms,” and “cardiovascular and renal symptoms.” Cronbach’s alpha coefficient for all factors was above 0.8, and the AFQOL total scores were significantly correlated with the physical and mental components of the SF-8 (rs = − 0.508 and − 0.400, respectively). CONCLUSIONS: The AFQOL scale assesses physical symptoms and social difficulties experienced by adult patients with Fabry disease. A strength of the scale is its ability to assess the impact of work and relationships on patients. The scale can be useful in objectively assessing QOL for a group or for individual patients. Future research should explore further aspects of the scale’s validity and reliability. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-022-00525-z.
format Online
Article
Text
id pubmed-9672224
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-96722242022-11-19 Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan Koto, Yuta Yamashita, Wakana Lee, Yoko Hadano, Nozomi Kokubu, Chikara Sakai, Norio J Patient Rep Outcomes Research BACKGROUND: Fabry disease is a rare X-linked lysosomal storage disorder. It is associated with physical distress and social challenges that may affect adults differently compared to pediatric patients. However, there is no disease-specific quality of life (QOL) scale that can provide a detailed assessment of QOL for adults with Fabry disease. Therefore, we aimed to determine the factor structure and assess the validity of a scale that was created to assess the QOL of adult patients with Fabry disease. This study was conducted in two phases. First, scale feasibility was confirmed through a questionnaire survey of nine patients. Second, a cross-sectional questionnaire survey of patients (aged ≥ 18 years) diagnosed with Fabry disease was conducted. Item development and refinement were conducted based on guidelines for scale development. Exploratory factor analysis was used to clarify the factor structure and confirm internal consistency. As a measure of QOL, construct validity was of the scale was verified based on its correlations with the Short Form-8 (SF-8) scale. RESULTS: The newly created Adult Fabry Disease QOL (AFQOL) scale comprises 39 items that cover five factors: “neuropathic pain and abdominal symptoms,” “impact on work and school,” “relationship challenges,” “ophthalmologic and otolaryngologic symptoms,” and “cardiovascular and renal symptoms.” Cronbach’s alpha coefficient for all factors was above 0.8, and the AFQOL total scores were significantly correlated with the physical and mental components of the SF-8 (rs = − 0.508 and − 0.400, respectively). CONCLUSIONS: The AFQOL scale assesses physical symptoms and social difficulties experienced by adult patients with Fabry disease. A strength of the scale is its ability to assess the impact of work and relationships on patients. The scale can be useful in objectively assessing QOL for a group or for individual patients. Future research should explore further aspects of the scale’s validity and reliability. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41687-022-00525-z. Springer International Publishing 2022-11-17 /pmc/articles/PMC9672224/ /pubmed/36394676 http://dx.doi.org/10.1186/s41687-022-00525-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Koto, Yuta
Yamashita, Wakana
Lee, Yoko
Hadano, Nozomi
Kokubu, Chikara
Sakai, Norio
Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan
title Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan
title_full Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan
title_fullStr Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan
title_full_unstemmed Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan
title_short Development and validation of a disease-specific quality of life scale for adult patients with Fabry disease in Japan
title_sort development and validation of a disease-specific quality of life scale for adult patients with fabry disease in japan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672224/
https://www.ncbi.nlm.nih.gov/pubmed/36394676
http://dx.doi.org/10.1186/s41687-022-00525-z
work_keys_str_mv AT kotoyuta developmentandvalidationofadiseasespecificqualityoflifescaleforadultpatientswithfabrydiseaseinjapan
AT yamashitawakana developmentandvalidationofadiseasespecificqualityoflifescaleforadultpatientswithfabrydiseaseinjapan
AT leeyoko developmentandvalidationofadiseasespecificqualityoflifescaleforadultpatientswithfabrydiseaseinjapan
AT hadanonozomi developmentandvalidationofadiseasespecificqualityoflifescaleforadultpatientswithfabrydiseaseinjapan
AT kokubuchikara developmentandvalidationofadiseasespecificqualityoflifescaleforadultpatientswithfabrydiseaseinjapan
AT sakainorio developmentandvalidationofadiseasespecificqualityoflifescaleforadultpatientswithfabrydiseaseinjapan